Advancements in Cancer Vaccines and AI in Epilepsy Management
A pancreatic cancer vaccine shows potential with increased T-cell responses, while an AI-driven model is transforming epilepsy management, highlighting the intersection of technology and healthcare.
- Continuous glucose monitoring reduced HbA1c from 8.8 to 7.2, indicating strong market demand for diabetes tech.
- KRAS-targeted vaccine showed robust T-cell response but failed disease-free survival, revealing R&D risks.
- AI integration in epilepsy management could disrupt traditional care, highlighting tech's strategic importance.







